E2F1 suppresses oxidative metabolism and endothelial differentiation of bone marrow progenitor cells

Shiyue Xu, Jun Tao, Liu Yang, Eric Zhang, Chan Boriboun, Junlan Zhou, Tianjiao Sun, Min Cheng, Kai Huang, Jiawei Shi, Nianguo Dong, Qinghua Liu, Ting C. Zhao, Hongyu Qiu, Robert Harris, Navdeep S. Chandel, Douglas W. Losordo, Gangjian Qin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Rationale: The majority of current cardiovascular cell therapy trials use bone marrow progenitor cells (BM PCs) and achieve only modest efficacy; the limited potential of these cells to differentiate into endothelial-lineage cells is one of the major barriers to the success of this promising therapy. We have previously reported that the E2F transcription factor 1 (E2F1) is a repressor of revascularization after ischemic injury. Objective: We sought to define the role of E2F1 in the regulation of BM PC function. Methods and Results: Ablation of E2F1 (E2F1 deficient) in mouse BM PCs increases oxidative metabolism and reduces lactate production, resulting in enhanced endothelial differentiation. The metabolic switch in E2F1-deficient BM PCs is mediated by a reduction in the expression of pyruvate dehydrogenase kinase 4 and pyruvate dehydrogenase kinase 2; overexpression of pyruvate dehydrogenase kinase 4 reverses the enhancement of oxidative metabolism and endothelial differentiation. Deletion of E2F1 in the BM increases the amount of PC-derived endothelial cells in the ischemic myocardium, enhances vascular growth, reduces infarct size, and improves cardiac function after myocardial infarction. Conclusion: Our results suggest a novel mechanism by which E2F1 mediates the metabolic control of BM PC differentiation, and strategies that inhibit E2F1 or enhance oxidative metabolism in BM PCs may improve the effectiveness of cell therapy.

Original languageEnglish (US)
Pages (from-to)701-711
Number of pages11
JournalCirculation research
Volume122
Issue number5
DOIs
StatePublished - Mar 1 2018

Fingerprint

E2F1 Transcription Factor
Bone Marrow Cells
Stem Cells
Cell- and Tissue-Based Therapy
Endothelial Cells
E2F Transcription Factors
Blood Vessels
Cell Differentiation
Lactic Acid
Myocardium
Myocardial Infarction

Keywords

  • Bone marrow
  • Cell differentiation
  • Endothelial progenitor cells
  • Myocardial infarction
  • Oxygen consumption
  • Stem cells

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

E2F1 suppresses oxidative metabolism and endothelial differentiation of bone marrow progenitor cells. / Xu, Shiyue; Tao, Jun; Yang, Liu; Zhang, Eric; Boriboun, Chan; Zhou, Junlan; Sun, Tianjiao; Cheng, Min; Huang, Kai; Shi, Jiawei; Dong, Nianguo; Liu, Qinghua; Zhao, Ting C.; Qiu, Hongyu; Harris, Robert; Chandel, Navdeep S.; Losordo, Douglas W.; Qin, Gangjian.

In: Circulation research, Vol. 122, No. 5, 01.03.2018, p. 701-711.

Research output: Contribution to journalArticle

Xu, S, Tao, J, Yang, L, Zhang, E, Boriboun, C, Zhou, J, Sun, T, Cheng, M, Huang, K, Shi, J, Dong, N, Liu, Q, Zhao, TC, Qiu, H, Harris, R, Chandel, NS, Losordo, DW & Qin, G 2018, 'E2F1 suppresses oxidative metabolism and endothelial differentiation of bone marrow progenitor cells', Circulation research, vol. 122, no. 5, pp. 701-711. https://doi.org/10.1161/CIRCRESAHA.117.311814
Xu, Shiyue ; Tao, Jun ; Yang, Liu ; Zhang, Eric ; Boriboun, Chan ; Zhou, Junlan ; Sun, Tianjiao ; Cheng, Min ; Huang, Kai ; Shi, Jiawei ; Dong, Nianguo ; Liu, Qinghua ; Zhao, Ting C. ; Qiu, Hongyu ; Harris, Robert ; Chandel, Navdeep S. ; Losordo, Douglas W. ; Qin, Gangjian. / E2F1 suppresses oxidative metabolism and endothelial differentiation of bone marrow progenitor cells. In: Circulation research. 2018 ; Vol. 122, No. 5. pp. 701-711.
@article{6819cd60621444be9172f319c284acff,
title = "E2F1 suppresses oxidative metabolism and endothelial differentiation of bone marrow progenitor cells",
abstract = "Rationale: The majority of current cardiovascular cell therapy trials use bone marrow progenitor cells (BM PCs) and achieve only modest efficacy; the limited potential of these cells to differentiate into endothelial-lineage cells is one of the major barriers to the success of this promising therapy. We have previously reported that the E2F transcription factor 1 (E2F1) is a repressor of revascularization after ischemic injury. Objective: We sought to define the role of E2F1 in the regulation of BM PC function. Methods and Results: Ablation of E2F1 (E2F1 deficient) in mouse BM PCs increases oxidative metabolism and reduces lactate production, resulting in enhanced endothelial differentiation. The metabolic switch in E2F1-deficient BM PCs is mediated by a reduction in the expression of pyruvate dehydrogenase kinase 4 and pyruvate dehydrogenase kinase 2; overexpression of pyruvate dehydrogenase kinase 4 reverses the enhancement of oxidative metabolism and endothelial differentiation. Deletion of E2F1 in the BM increases the amount of PC-derived endothelial cells in the ischemic myocardium, enhances vascular growth, reduces infarct size, and improves cardiac function after myocardial infarction. Conclusion: Our results suggest a novel mechanism by which E2F1 mediates the metabolic control of BM PC differentiation, and strategies that inhibit E2F1 or enhance oxidative metabolism in BM PCs may improve the effectiveness of cell therapy.",
keywords = "Bone marrow, Cell differentiation, Endothelial progenitor cells, Myocardial infarction, Oxygen consumption, Stem cells",
author = "Shiyue Xu and Jun Tao and Liu Yang and Eric Zhang and Chan Boriboun and Junlan Zhou and Tianjiao Sun and Min Cheng and Kai Huang and Jiawei Shi and Nianguo Dong and Qinghua Liu and Zhao, {Ting C.} and Hongyu Qiu and Robert Harris and Chandel, {Navdeep S.} and Losordo, {Douglas W.} and Gangjian Qin",
year = "2018",
month = "3",
day = "1",
doi = "10.1161/CIRCRESAHA.117.311814",
language = "English (US)",
volume = "122",
pages = "701--711",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - E2F1 suppresses oxidative metabolism and endothelial differentiation of bone marrow progenitor cells

AU - Xu, Shiyue

AU - Tao, Jun

AU - Yang, Liu

AU - Zhang, Eric

AU - Boriboun, Chan

AU - Zhou, Junlan

AU - Sun, Tianjiao

AU - Cheng, Min

AU - Huang, Kai

AU - Shi, Jiawei

AU - Dong, Nianguo

AU - Liu, Qinghua

AU - Zhao, Ting C.

AU - Qiu, Hongyu

AU - Harris, Robert

AU - Chandel, Navdeep S.

AU - Losordo, Douglas W.

AU - Qin, Gangjian

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Rationale: The majority of current cardiovascular cell therapy trials use bone marrow progenitor cells (BM PCs) and achieve only modest efficacy; the limited potential of these cells to differentiate into endothelial-lineage cells is one of the major barriers to the success of this promising therapy. We have previously reported that the E2F transcription factor 1 (E2F1) is a repressor of revascularization after ischemic injury. Objective: We sought to define the role of E2F1 in the regulation of BM PC function. Methods and Results: Ablation of E2F1 (E2F1 deficient) in mouse BM PCs increases oxidative metabolism and reduces lactate production, resulting in enhanced endothelial differentiation. The metabolic switch in E2F1-deficient BM PCs is mediated by a reduction in the expression of pyruvate dehydrogenase kinase 4 and pyruvate dehydrogenase kinase 2; overexpression of pyruvate dehydrogenase kinase 4 reverses the enhancement of oxidative metabolism and endothelial differentiation. Deletion of E2F1 in the BM increases the amount of PC-derived endothelial cells in the ischemic myocardium, enhances vascular growth, reduces infarct size, and improves cardiac function after myocardial infarction. Conclusion: Our results suggest a novel mechanism by which E2F1 mediates the metabolic control of BM PC differentiation, and strategies that inhibit E2F1 or enhance oxidative metabolism in BM PCs may improve the effectiveness of cell therapy.

AB - Rationale: The majority of current cardiovascular cell therapy trials use bone marrow progenitor cells (BM PCs) and achieve only modest efficacy; the limited potential of these cells to differentiate into endothelial-lineage cells is one of the major barriers to the success of this promising therapy. We have previously reported that the E2F transcription factor 1 (E2F1) is a repressor of revascularization after ischemic injury. Objective: We sought to define the role of E2F1 in the regulation of BM PC function. Methods and Results: Ablation of E2F1 (E2F1 deficient) in mouse BM PCs increases oxidative metabolism and reduces lactate production, resulting in enhanced endothelial differentiation. The metabolic switch in E2F1-deficient BM PCs is mediated by a reduction in the expression of pyruvate dehydrogenase kinase 4 and pyruvate dehydrogenase kinase 2; overexpression of pyruvate dehydrogenase kinase 4 reverses the enhancement of oxidative metabolism and endothelial differentiation. Deletion of E2F1 in the BM increases the amount of PC-derived endothelial cells in the ischemic myocardium, enhances vascular growth, reduces infarct size, and improves cardiac function after myocardial infarction. Conclusion: Our results suggest a novel mechanism by which E2F1 mediates the metabolic control of BM PC differentiation, and strategies that inhibit E2F1 or enhance oxidative metabolism in BM PCs may improve the effectiveness of cell therapy.

KW - Bone marrow

KW - Cell differentiation

KW - Endothelial progenitor cells

KW - Myocardial infarction

KW - Oxygen consumption

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=85047745818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047745818&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.117.311814

DO - 10.1161/CIRCRESAHA.117.311814

M3 - Article

C2 - 29358228

AN - SCOPUS:85047745818

VL - 122

SP - 701

EP - 711

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 5

ER -